Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Has Consensus Price Target of $596.44

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twenty-eight ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, twenty-five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $596.44.

A number of research firms have weighed in on VRTX. Cantor Fitzgerald lifted their price objective on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Evercore lifted their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. Weiss Ratings downgraded Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday. Barclays upped their price objective on Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Finally, Scotiabank raised their price objective on shares of Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 3rd.

Check Out Our Latest Analysis on VRTX

Vertex Pharmaceuticals Stock Down 0.2%

NASDAQ:VRTX opened at $547.03 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. The company’s fifty day moving average price is $523.04 and its 200-day moving average price is $483.19. Vertex Pharmaceuticals has a 1-year low of $412.27 and a 1-year high of $568.67. The firm has a market capitalization of $138.69 billion, a P/E ratio of 35.20, a PEG ratio of 2.90 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.80 earnings per share. As a group, equities research analysts anticipate that Vertex Pharmaceuticals will post 16.10 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Guidance Capital Inc. boosted its stake in shares of Vertex Pharmaceuticals by 0.9% during the 3rd quarter. Guidance Capital Inc. now owns 2,230 shares of the pharmaceutical company’s stock worth $1,234,000 after acquiring an additional 19 shares in the last quarter. Bangor Savings Bank increased its stake in shares of Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock valued at $2,220,000 after purchasing an additional 20 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Vertex Pharmaceuticals by 4.7% in the 3rd quarter. Texas Capital Bank Wealth Management Services Inc now owns 449 shares of the pharmaceutical company’s stock valued at $235,000 after purchasing an additional 20 shares in the last quarter. Trust Point Inc. raised its holdings in Vertex Pharmaceuticals by 2.7% in the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock worth $394,000 after purchasing an additional 21 shares during the period. Finally, Integrated Advisors Network LLC raised its holdings in Vertex Pharmaceuticals by 1.4% in the 3rd quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock worth $850,000 after purchasing an additional 22 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

See Also

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.